Advertisement
Advertisement
U.S. markets open in 2 hours 7 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Yumanity Therapeutics, Inc. (YMTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
9.04-0.20 (-2.16%)
At close: 4:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close9.24
Open9.26
Bid0.00 x 900
Ask0.00 x 900
Day's Range8.84 - 9.41
52 Week Range8.21 - 26.20
Volume89,166
Avg. Volume150,978
Market Cap93.169M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-9.76
Earnings DateNov 15, 2021 - Nov 19, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est36.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for YMTX

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Yumanity Therapeutics, Inc.
    Market Digest: CNI, NDAQ, BK, GILD, ISRG, MKTX, NFLX, SWXAs Earnings Roll in, the Economy Rolls on
    Rating
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more
  • GlobeNewswire

    Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the grant to an employee of non-statutory stock options for the purchase of up to an aggregate of 4,000 shares of Yumanity’s common stock. The options will vest over four years, with 25 percent of the shares vesting on the first anniversary of t

  • GlobeNewswire

    Yumanity Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the grant to one new employee of a non-statutory stock option for the purchase of up to an aggregate of 30,000 shares of Yumanity’s common stock. The option will vest over four years, with 25 percent of the shares vesting on the first anniversa

  • GlobeNewswire

    Yumanity Therapeutics to Present at the H.C. Wainwright 23rd Global Investment Conference

    BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 23rd Global Investment Conference. The presentation will be available on-demand via the conference portal and through the Company's web

Advertisement
Advertisement